Engineered immune cells aim to calm liver damage in first human trial
Disease control
Recruiting now
This study tests a new treatment called RTX001 for people with severe liver cirrhosis that has caused complications. RTX001 uses the patient's own immune cells (macrophages) that are modified in a lab to reduce inflammation and scarring in the liver. The trial will enroll 30 adul…
Phase: PHASE1, PHASE2 • Sponsor: Resolution Therapeutics Limited • Aim: Disease control
Last updated May 11, 2026 20:40 UTC